Spots Global Cancer Trial Database for multiple myeloma (mm)
Every month we try and update this database with for multiple myeloma (mm) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | NCT03263637 | Relapsed or Ref... Acute Myeloid L... Acute Lymphocyt... Chronic Lymphoc... High Risk Myelo... Chronic Myelomo... Richter's Syndr... B-cell Non-Hodg... T-cell Non-Hodg... Small Lymphocyt... Multiple Myelom... | AZD4573 | 18 Years - 130 Years | AstraZeneca | |
| Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma | NCT05673967 | Relapsed and Re... | Non-Interventio... | 18 Years - | Regeneron Pharmaceuticals | |
| Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. | NCT02203643 | MULTIPLE MYELOM... | Carfilzomib Cyclophosphamid... Lenalidomide Dexamethasone | 18 Years - | University of Turin, Italy | |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma | NCT04649073 | Multiple Myelom... | OPC-415 | 20 Years - 80 Years | Otsuka Pharmaceutical Co., Ltd. | |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS) | NCT01344707 | Advanced Hemato... | 4SC-202 | 18 Years - | 4SC AG | |
| Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases | NCT00434447 | Bone Neoplasms | Zoledronic acid | 18 Years - | Novartis | |
| Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America | NCT02559583 | Multiple Myelom... Leukemia Lymphoid Lymphoma Non-Hodgkin | Chronic Lymphoc... Multiple Myelom... Non-Hodgkin's l... | 18 Years - | Janssen-Cilag Ltd. | |
| Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | NCT00710528 | Chronic Lymphoc... Lymphoma, Non-H... Acute Myeloid L... Multiple Myelom... | CAL-101 | 18 Years - | Gilead Sciences | |
| VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) | NCT04702425 | Non-Hodgkin Lym... Acute Myeloid L... Multiple Myelom... | VOB560 MIK665 | 18 Years - | Novartis | |
| Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America | NCT02559583 | Multiple Myelom... Leukemia Lymphoid Lymphoma Non-Hodgkin | Chronic Lymphoc... Multiple Myelom... Non-Hodgkin's l... | 18 Years - | Janssen-Cilag Ltd. | |
| Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma | NCT01919086 | Multiple Myelom... | Bortezomib Dexamethasone Lenalidomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) | NCT04702425 | Non-Hodgkin Lym... Acute Myeloid L... Multiple Myelom... | VOB560 MIK665 | 18 Years - | Novartis | |
| B-Cell Hematologic Malignancy Vaccination Registry | NCT02298816 | Monoclonal Gamm... Multiple Myelom... Waldenstrom Mac... Lymphocytosis Lymphoma, Non-H... B-Cell Chronic ... Hematological M... | - | Aurora Health Care | ||
| A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma | NCT05955508 | Smoldering Mult... | Linvoseltamab | 18 Years - | Regeneron Pharmaceuticals | |
| B-Cell Hematologic Malignancy Vaccination Registry | NCT02298816 | Monoclonal Gamm... Multiple Myelom... Waldenstrom Mac... Lymphocytosis Lymphoma, Non-H... B-Cell Chronic ... Hematological M... | - | Aurora Health Care | ||
| Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma | NCT01919086 | Multiple Myelom... | Bortezomib Dexamethasone Lenalidomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of INCB053914 in Subjects With Advanced Malignancies | NCT02587598 | Solid Tumors | INCB053914 I-DAC (Intermed... Azacitidine Ruxolitinib | 18 Years - | Incyte Corporation | |
| Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer | NCT02240537 | Acute Myelogeno... Multiple Myelom... Myelodysplastic... Smoldering Mult... | Sargramostim BB-MPI-03 Montanide | 18 Years - | Benovus Bio, Inc. | |
| Tumor Registry of Lymphatic Neoplasia | NCT00889798 | Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | 18 Years - | iOMEDICO AG | ||
| CART-38 in Adult AML and MM Patients | NCT05442580 | Acute Myeloid L... Multiple Myelom... | 3x10(6) CART-38... 7x10(5) CART-38... 7x10(6) CART-38... 3x10(7) CART-38... Cyclophosphamid... Fludarabine | 18 Years - | University of Pennsylvania | |
| Phase I Study of Milatuzumab for Graft Versus Host Disease | NCT01663766 | GVHD (Acute or ... Acute Myeloid o... Myelodysplastic... Chronic Myeloge... Multiple Myelom... Non-Hodgekin Ly... Chronic Lymphoc... | milatuzumab | 18 Years - | Gilead Sciences | |
| Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. | NCT02203643 | MULTIPLE MYELOM... | Carfilzomib Cyclophosphamid... Lenalidomide Dexamethasone | 18 Years - | University of Turin, Italy | |
| VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) | NCT04702425 | Non-Hodgkin Lym... Acute Myeloid L... Multiple Myelom... | VOB560 MIK665 | 18 Years - | Novartis | |
| An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | NCT03844048 | Chronic Lymphoc... Acute Myeloid L... Multiple Myelom... Non-Hodgkin's L... Acute Lymphobla... Cancer | Venetoclax | - | AbbVie | |
| A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma | NCT05955508 | Smoldering Mult... | Linvoseltamab | 18 Years - | Regeneron Pharmaceuticals | |
| A Study of WVT078 in Patients With Multiple Myeloma (MM) | NCT04123418 | Multiple Myelom... | WVT078 WHG626 | 18 Years - 99 Years | Novartis | |
| A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies | NCT05908409 | Multiple Myelom... Diffuse Large B... Double Hit Lymp... High Grade B-Ce... Chronic Lymphoc... Triple Hit Lymp... | IDP-121 | 18 Years - | IDP Discovery Pharma S.L. | |
| Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma | NCT02920697 | Chronic Lymphoc... B-Cell Non-Hodg... Multiple Myelom... | S 55746 | 18 Years - | Servier | |
| Study of INCB053914 in Subjects With Advanced Malignancies | NCT02587598 | Solid Tumors | INCB053914 I-DAC (Intermed... Azacitidine Ruxolitinib | 18 Years - | Incyte Corporation | |
| Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients | NCT04172467 | Secondary Immun... | non-interventio... | 18 Years - | AIO-Studien-gGmbH | |
| Tumor Registry of Lymphatic Neoplasia | NCT00889798 | Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | 18 Years - | iOMEDICO AG | ||
| Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | NCT01413568 | Acute Myeloid L... Adult Acute Lym... Chronic Myeloge... Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... Myelodysplastic... Myeloproliferat... | POL6326 Leukapheresis PBSC Transplant | 18 Years - 75 Years | Polyphor Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
